Clinical Trial Update: Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m [Phase 3]

View source ↗

Summary

Phase 3 trial update of Tritanrix-HepB/Hib-MenAC and Mencevax ACWY vaccines with completed status and results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Haemophilus Influenzae Type Disease
• Hepatitis B
• Meningococcal Disease
• Pertussis
• Tetanus

Drugs mentioned

• Mencevax ACWY
• Tritanrix-HepB/Hib-MenAC

Snippet

Sponsor: GlaxoSmithKline | Conditions: Whole Cell Pertussis, Haemophilus Influenzae Type b | Phase 3 | Status: COMPLETED | Results posted: 2018-09-17